Affiliation:
1. iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal
2. Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal
Abstract
Gene therapy relies on the delivery of genetic material to the patient’s cells in order to provide a therapeutic treatment. Two of the currently most used and efficient delivery systems are the lentiviral (LV) and adeno-associated virus (AAV) vectors. Gene therapy vectors must successfully attach, enter uncoated, and escape host restriction factors (RFs), before reaching the nucleus and effectively deliver the therapeutic genetic instructions to the cell. Some of these RFs are ubiquitously expressed in mammalian cells, while others are cell-specific, and others still are expressed only upon induction by danger signals as type I interferons. Cell restriction factors have evolved to protect the organism against infectious diseases and tissue damage. These restriction factors can be intrinsic, directly acting on the vector, or related with the innate immune response system, acting indirectly through the induction of interferons, but both are intertwined. The innate immunity is the first line of defense against pathogens and, as such cells derived from myeloid progenitors (but not only), are well equipped with RFs to detect pathogen-associated molecular patterns (PAMPs). In addition, some non-professional cells, such as epithelial cells, endothelial cells, and fibroblasts, play major roles in pathogen recognition. Unsurprisingly, foreign DNA and RNA molecules are among the most detected PAMPs. Here, we review and discuss identified RFs that block LV and AAV vector transduction, hindering their therapeutic efficacy.
Funder
Fundação para a Ciência e Tecnologia/Ministério da Educação e Ciência
FEDER
Reference154 articles.
1. The approved gene therapy drugs worldwide: From 1998 to 2019;Ma;Biotechnol. Adv.,2020
2. Agency, E.M. (2001). Directive 2001/83/EC of the European Parliament and of the Council Of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use, European Parliament. Directive 2001/83/EC (Annex I Part IV).
3. Evolutionary conflicts and adverse effects of antiviral factors;Sauter;Elife,2021
4. Pathogen recognition and innate immunity;Akira;Cell,2006
5. Immune Responses to Viral Gene Therapy Vectors;Shirley;Mol. Ther.,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献